According to TipRanks.com, Prasad is a 5-star analyst with an average return of 23.2% and a 62.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.
Currently, the analyst consensus on Alexion Pharmaceuticals is a Strong Buy with an average price target of $146.58, representing a 28.8% upside. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock.
Based on Alexion Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $468 million. In comparison, last year the company had a net profit of $331 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P.